Senior Director, Companion Diagnostics
- Employer
- Daiichi Sankyo
- Location
- Edison, New Jersey, United States
- Start date
- Sep 8, 2019
View more
- Discipline
- Quality, Quality Control
- Required Education
- Doctorate/PHD/MD
- Position Type
- Full time
- Hotbed
- Pharm Country
Job Details
The primary responsibilities of this position are to lead CDx project teams independently, contribute to strategic decisions for projects w/ a CDx component, collaborate very actively with leadership from other DS functions (Regulatory, Commercial, QA, IPTs, etc) to execute CDx strategies, contribute to due diligence/licensing decisions with a CDx component and represent GCDxC in KOL & CDx regulatory interactions
Responsibilities:
Lead CDx project teams in all areas of CDx development, registration, and commercialization independently
Leads CDx Partner evaluation and selection activities independently
Participates in cross-functional strategic decisions involving CDx. Contributes to global and regional strategic decisions
May independently write publications & regulatory documents
May be responsible for performance management and development of direct reports and department
Represents GCDxC in KOL and global CDx regulatory interactions. Leads KOL & regulatory interactions for programs with CDx component
Participates in due diligence activities
Education:
Experience:
MD, PhD, or PharmD with 8+ years industry experience
Or equivalent experience
People management experience (for managerial track)
Job Title
Senior Director, Companion Diagnostics
City
Edison
Functional Area
Global Oncology R&D
State
New Jersey
Company
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.
With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.
For more information, please visit: www.daiichisankyo.com.
Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.
STOCK EXCHANGE: Tokyo Stock Exchange
STOCK SYMBOL: 4568
- Website
- http://www.daiichisankyo.com/
- Phone
- (908) 992-6400
- Location
-
211 Mt. Airy Road
Basking Ridge
New Jersey
07920
United States
Get job alerts
Create a job alert and receive personalized job recommendations straight to your inbox.
Create alert